< Back to catalogue
Dulsevia®
15 Ιουλίου, 2026Hedimal®
15 Ιουλίου, 2026PHARMAZAC
Everolimus/Pharmazac
Everolimus | Antineoplastic agent | Oncology
| EVEROLIMUS/PHARMAZAC TABLET 5MG/TAB BTx30 |
| EVEROLIMUS/PHARMAZAC TABLET 10MG/TAB BTx30 |
| EVEROLIMUS/PHARMAZAC TABLET 5MG/TAB BTx30 |
| EVEROLIMUS/PHARMAZAC TABLET 10MG/TAB BTx30 |
| THERAPEUTIC AREA | |
|---|---|
| PRESCRIPTION REQUIREMENT | |
| PHARMACOLOGICAL CLASS | |
| MARKETING AUTHORISATION HOLDER | Pharmazac S.A. |
| BUSINESS UNIT | |
| ACTIVE SUBSTANCE |
